Advertisement

Document › Details
Polyphor Ltd.. (9/10/21). "Press Release: Polyphor and EnBiotix Announce Closing of Purchase Agreement of Inhaled Murepavadin by EnBiotix". Allschwil.
![]() |
Organisation | Polyphor Ltd. (SIX: POLN) |
Today | Spexis AG (SIX: ???) | |
Group | Spexis (Group) | |
Organisation 2 | EnBiotix Inc. | |
Group | Spexis (Group) | |
![]() |
Product | murepavadin (POL7080) |
Product 2 | investment banking | |
![]() |
Person | Levett, Hernán (Polyphor 202001 CFO) |
Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today announced closing of the previously announced purchase agreement of inhaled murepavadin. As a result of closing the transaction, Polyphor received the agreed payment of 2'599'655 of common shares of EnBiotix (15.4% fully diluted of EnBiotix) at an agreed valuation of USD 10 million.
Following the closing of the inhaled murepavadin purchase agreement, the companies will take the next steps with respect to the merger agreement, which was signed simultaneously. The planned merger is subject to a number of closing conditions, including approval by Polyphor and EnBiotix shareholders, and is expected to be closed in Q4 2021.
For further information please contact:
For Investors:
Hernan Levett
Chief Financial Officer
Polyphor Ltd.
+41 61 567 16 00
IR@polyphor.com For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
About Polyphor
Polyphor is a research-oriented Swiss biopharmaceutical company with a leading macrocyclic peptide technology platform. Polyphor is headquartered in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). www.polyphor.com.
About EnBiotix
Enbiotix is a privately-held, rare disease company with an initial focus on chronic respiratory diseases. EnBiotix is headquartered in Boston, Massachussets, USA with its affiliate, EnBiotix, GmbH based in Leipzig, Germany. www.enbiotix.com
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Record changed: 2021-11-16 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Spexis (Group)
- [1] Polyphor Ltd.. (29/10/21). "Press Release: Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting". Allschwil....
- [2] Polyphor Ltd.. (9/1/21). "Press Release: Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix". Allschwil....
- [3] Polyphor Ltd.. (7/16/21). "Press Release: Polyphor Provides Update on the Future of the FORTRESS Study of Balixafortide and Announces Initial Restructuring Steps". Allschwil....
- [4] Polyphor Ltd.. (6/28/21). "Press Release: Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients with Advanced HER2 Negative Breast cancer". Allschwil....
- [5] Polyphor Ltd.. (10/14/20). "Press Release: Polyphor Receives CARB-X Award of up to USD 18.44 Million to Support Development of New Antibiotic Program". Allschwil....
- [6] Polyphor Ltd.. (7/28/20). "Press Release: Polyphor Strengthens Financial Flexibility with CHF 19.3 million Equity-linked Financing". Allschwil....
- [7] Polyphor Ltd.. (1/23/20). "Press Release: Polyphor Appoints Gökhan Batur as Chief Executive Officer". Allschwil....
- [8] Polyphor Ltd.. (6/27/19). "Press Release: Polyphor Appoints Frank Weber as New Chief Medical and Development Officer". Allschwil....
- [9] Polyphor Ltd.. (5/29/19). "Press Release: Polyphor and the University of Zurich Receive an Award from Innosuisse to Accelerate the Development of a New Class of Antibiotics Inhibiting the LPS Transport Pathway". Allschwil....
- [10] Polyphor Ltd.. (5/17/19). "Press Release: Polyphor Announces Presentation of New Survival Data on Balixafortide at the ASCO Annual Meeting 2019". Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top